Goldenrod Therapeutics
Develops novel brain-penetrant therapies targeting neuroinflammation and neuronal signaling pathways
$6.5MSeed
Role not disclosedFP
Fannin Partners
Activity from announced rounds
Activity in this selectionUnited States · Jun 30, 2026 · Jun 1, 2026
- Rounds participated in
- 1
- Confirmed lead rounds
- — 1 roles undisclosed
- New companies
- 1 First participation on record · 0 follow-on
- Funding in participating rounds
- $6.5M 1 disclosed · full round size, not this investor’s share